NRAS and melanoma: In NRAS mutant patients of the discovery cohort, NOTCH4-Mut melanoma had longer OS (mOS: 34.93 months vs. 6.43 months, HR = 0.37, 95% CI: 0.09–1.61, P = 0.17) than wildtype melanoma, but there was no statistical difference.